The increased titres and productivity of the latest generation of cell lines are now well documented and understood. The rate limiting steps and capacity constraints within biopharmaceutical production have now moved to the downstream unit operations. This meeting aims to explain each of these unit operations and may offer some possible solutions.
Explore
Membership
